© Drug Hunter Inc. 2018-2023
Home > AZD4573
short engagement, selective CDK9 kinase inh.
IV treatment in Ph. I for RR-heme cancers
shortened t1/2 from prior preclin. candidate
J. Med. Chem., Dec. 11, 2020
AstraZeneca, Cambridge, UK / Boston, MA
AstraZeneca selective CDK9 kinase inhibitor
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year